Works matching AU Omori, Shota

Results: 57
    1
    2
    3
    4

    Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma.

    Published in:
    Molecular & Clinical Oncology, 2017, v. 6, n. 5, p. 718, doi. 10.3892/mco.2017.1198
    By:
    • NORIMITSU KASAHARA;
    • KAZUSHIGE WAKUDA;
    • SHOTA OMORI;
    • KAZUHISA NAKASHIMA;
    • AKIRA ONO;
    • TETSUHIKO TAIRA;
    • HIROTSUGU KENMOTSU;
    • TATEAKI NAITO;
    • HARUYASU MURAKAMI;
    • KEITA MORI;
    • REIKO WATANABE;
    • MASAHIRO ENDO;
    • TAKASHI NAKAJIMA;
    • MASANOBU YAMADA;
    • TOSHIAKI TAKAHASHI
    Publication type:
    Article
    5
    6

    Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors.

    Published in:
    Japanese Journal of Clinical Oncology, 2021, v. 51, n. 12, p. 1736, doi. 10.1093/jjco/hyab158
    By:
    • Wakuda, Kazushige;
    • Yabe, Michitoshi;
    • Kodama, Hiroaki;
    • Nishioka, Naoya;
    • Miyawaki, Taichi;
    • Miyawaki, Eriko;
    • Mamesaya, Nobuaki;
    • Kobayashi, Haruki;
    • Omori, Shota;
    • Ono, Akira;
    • Kenmotsu, Hirotsugu;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Shimizu, Tetsuo;
    • Gon, Yasuhiro;
    • Takahashi, Toshiaki
    Publication type:
    Article
    7

    A multi-institutional randomized phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin as regimens for concurrent chemoradiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG1914

    Published in:
    Japanese Journal of Clinical Oncology, 2021, v. 51, n. 5, p. 836, doi. 10.1093/jjco/hyab025
    By:
    • Shimoyama, Ryo;
    • Omori, Shota;
    • Nomura, Shogo;
    • Kenmotsu, Hirotsugu;
    • Takahashi, Toshiaki;
    • Harada, Hideyuki;
    • Ishikura, Satoshi;
    • Mizutani, Tomonori;
    • Ando, Masahiko;
    • Kataoka, Tomoko;
    • Fukuda, Haruhiko;
    • Ohe, Yuichiro;
    • Group, the Lung Cancer Study Group in the Japan Clinical Oncology
    Publication type:
    Article
    8
    9
    10

    Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 9, p. 2455, doi. 10.1007/s00432-021-03784-3
    By:
    • Omori, Shota;
    • Muramatsu, Koji;
    • Kawata, Takuya;
    • Miyawaki, Eriko;
    • Miyawaki, Taichi;
    • Mamesaya, Nobuaki;
    • Kawamura, Takahisa;
    • Kobayashi, Haruki;
    • Nakashima, Kazuhisa;
    • Wakuda, Kazushige;
    • Ono, Akira;
    • Kenmotsu, Hirotsugu;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Sugino, Takashi;
    • Takahashi, Toshiaki
    Publication type:
    Article
    11
    12
    13

    Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L.

    Published in:
    Cancer Science, 2022, v. 113, n. 1, p. 221, doi. 10.1111/cas.15176
    By:
    • Sakata, Shinya;
    • Otsubo, Kohei;
    • Yoshida, Hisako;
    • Ito, Kentaro;
    • Nakamura, Atsushi;
    • Teraoka, Shunsuke;
    • Matsumoto, Naohisa;
    • Shiraishi, Yoshimasa;
    • Haratani, Koji;
    • Tamiya, Motohiro;
    • Ikeda, Satoshi;
    • Miura, Satoru;
    • Tanizaki, Junko;
    • Omori, Shota;
    • Yoshioka, Hiroshige;
    • Hata, Akito;
    • Yamamoto, Nobuyuki;
    • Nakagawa, Kazuhiko
    Publication type:
    Article
    14

    Proposing synchronous oligometastatic non–small‐cell lung cancer based on progression after first‐line systemic therapy.

    Published in:
    Cancer Science, 2021, v. 112, n. 1, p. 359, doi. 10.1111/cas.14707
    By:
    • Miyawaki, Taichi;
    • Wakuda, Kazushige;
    • Kenmotsu, Hirotsugu;
    • Miyawaki, Eriko;
    • Mamesaya, Nobuaki;
    • Kobayashi, Haruki;
    • Omori, Shota;
    • Ono, Akira;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Notsu, Akifumi;
    • Mori, Keita;
    • Harada, Hideyuki;
    • Endo, Masahiro;
    • Ohde, Yasuhisa;
    • Takahashi, Kazuhisa;
    • Takahashi, Toshiaki
    Publication type:
    Article
    15
    16
    17
    18
    19
    20
    21

    Multi-institutional feasibility study of intensity-modulated radiotherapy with chemotherapy for locally advanced non-small cell lung cancer.

    Published in:
    International Journal of Clinical Oncology, 2022, v. 27, n. 6, p. 1025, doi. 10.1007/s10147-022-02151-7
    By:
    • Harada, Hideyuki;
    • Omori, Shota;
    • Mori, Keita;
    • Konno, Masahiro;
    • Murakami, Haruyasu;
    • Imagumbai, Toshiyuki;
    • Fukuda, Haruyuki;
    • Nakamatsu, Kiyoshi;
    • Kimura, Tomoki;
    • Tanabe, Hiroaki;
    • Fujita, Hideki;
    • Tatebe, Hitoshi;
    • Fujitaka, Kazunori;
    • Nishimura, Yasumasa
    Publication type:
    Article
    22

    Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.

    Published in:
    International Journal of Clinical Oncology, 2021, v. 26, n. 4, p. 659, doi. 10.1007/s10147-020-01856-x
    By:
    • Mamesaya, Nobuaki;
    • Muramatsu, Koji;
    • Yabe, Michitoshi;
    • Kodama, Hiroaki;
    • Nishioka, Naoya;
    • Miyawaki, Taichi;
    • Miyawaki, Eriko;
    • Kobayashi, Haruki;
    • Omori, Shota;
    • Wakuda, Kazushige;
    • Ono, Akira;
    • Kenmotsu, Hirotsugu;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Harada, Hideyuki;
    • Sugino, Takashi;
    • Shimizu, Tetsuo;
    • Gon, Yasuhiro;
    • Takahashi, Toshiaki
    Publication type:
    Article
    23

    Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.

    Published in:
    International Journal of Clinical Oncology, 2018, v. 23, n. 6, p. 1052, doi. 10.1007/s10147-018-1305-4
    By:
    • Omori, Shota;
    • Kenmotsu, Hirotsugu;
    • Abe, Masato;
    • Watanabe, Reiko;
    • Sugino, Takashi;
    • Kobayashi, Haruki;
    • Nakashima, Kazuhisa;
    • Wakuda, Kazushige;
    • Ono, Akira;
    • Taira, Tetsuhiko;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Ohde, Yasuhisa;
    • Endo, Masahiro;
    • Akiyama, Yasuto;
    • Nakajima, Takashi;
    • Takahashi, Toshiaki
    Publication type:
    Article
    24
    25

    The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.

    Published in:
    International Journal of Clinical Oncology, 2015, v. 20, n. 4, p. 668, doi. 10.1007/s10147-014-0761-8
    By:
    • Ko, Ryo;
    • Kenmotsu, Hirotsugu;
    • Hisamatsu, Yasushi;
    • Akamatsu, Hiroaki;
    • Omori, Shota;
    • Nakashima, Kazuhisa;
    • Oyakawa, Takuya;
    • Wakuda, Kazushige;
    • Shukuya, Takehito;
    • Ono, Akira;
    • Imai, Hisao;
    • Taira, Tetsuhiko;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Mori, Keita;
    • Endo, Masahiro;
    • Ohde, Yasuhisa;
    • Takahashi, Kazuhisa;
    • Takahashi, Toshiaki
    Publication type:
    Article
    26
    27

    Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 2, p. 1451, doi. 10.1002/cam4.5035
    By:
    • Miyawaki, Taichi;
    • Kenmotsu, Hirotsugu;
    • Doshita, Kosei;
    • Kodama, Hiroaki;
    • Nishioka, Naoya;
    • Iida, Yuko;
    • Miyawaki, Eriko;
    • Mamesaya, Nobuaki;
    • Kobayashi, Haruki;
    • Omori, Shota;
    • Ko, Ryo;
    • Wakuda, Kazushige;
    • Ono, Akira;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Mori, Keita;
    • Harada, Hideyuki;
    • Endo, Masahiro;
    • Takahashi, Kazuhisa;
    • Takahashi, Toshiaki
    Publication type:
    Article
    28

    Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation.

    Published in:
    Cancer Medicine, 2021, v. 10, n. 21, p. 7503, doi. 10.1002/cam4.4268
    By:
    • Kodama, Hiroaki;
    • Kenmotsu, Hirotsugu;
    • Kawabata, Takanori;
    • Notsu, Akifumi;
    • Yabe, Michitoshi;
    • Nishioka, Naoya;
    • Miyawaki, Eriko;
    • Miyawaki, Taichi;
    • Mamesaya, Nobuaki;
    • Kobayashi, Haruki;
    • Omori, Shota;
    • Wakuda, Kazushige;
    • Ono, Akira;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Takahashi, Toshiaki
    Publication type:
    Article
    29
    30
    31
    32
    33

    Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study.

    Published in:
    2017
    By:
    • Tateaki Naito;
    • Taro Okayama;
    • Takashi Aoyama;
    • Takuya Ohashi;
    • Yoshiyuki Masuda;
    • Madoka Kimura;
    • Hitomi Shiozaki;
    • Haruyasu Murakami;
    • Hirotsugu Kenmotsu;
    • Tetsuhiko Taira;
    • Akira Ono;
    • Kazushige Wakuda;
    • Hisao Imai;
    • Takuya Oyakawa;
    • Takeshi Ishii;
    • Shota Omori;
    • Kazuhisa Nakashima;
    • Masahiro Endo;
    • Katsuhiro Omae;
    • Keita Mori
    Publication type:
    journal article
    34

    Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer.

    Published in:
    2017
    By:
    • Tateaki Naito;
    • Taro Okayama;
    • Takashi Aoyama;
    • Takuya Ohashi;
    • Yoshiyuki Masuda;
    • Madoka Kimura;
    • Hitomi Shiozaki;
    • Haruyasu Murakami;
    • Hirotsugu Kenmotsu;
    • Tetsuhiko Taira;
    • Akira Ono;
    • Kazushige Wakuda;
    • Hisao Imai;
    • Takuya Oyakawa;
    • Takeshi Ishii;
    • Shota Omori;
    • Kazuhisa Nakashima;
    • Masahiro Endo;
    • Katsuhiro Omae;
    • Keita Mori
    Publication type:
    journal article
    35
    36

    A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.

    Published in:
    Japanese Journal of Clinical Oncology, 2017, v. 47, n. 9, p. 840, doi. 10.1093/jjco/hyx084
    By:
    • Kazuhisa Nakashima;
    • Haruyasu Murakami;
    • Kouichi Yokoyama;
    • Shota Omori;
    • Kazushige Wakuda;
    • Akira Ono;
    • Hirotsugu Kenmotsu;
    • Tateaki Naito;
    • Fumie Nishiyama;
    • Mami Kikugawa;
    • Masayo Kaneko;
    • Yumiko Iwamoto;
    • Satomi Koizumi;
    • Keita Mori;
    • Takeshi Isobe;
    • Toshiaki Takahashi
    Publication type:
    Article
    37

    Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in advanced non‐small cell lung cancer.

    Published in:
    Thoracic Cancer, 2022, v. 13, n. 14, p. 2064, doi. 10.1111/1759-7714.14529
    By:
    • Miyawaki, Taichi;
    • Naito, Tateaki;
    • Doshita, Kosei;
    • Kodama, Hiroaki;
    • Mori, Mikiko;
    • Nishioka, Naoya;
    • Iida, Yuko;
    • Miyawaki, Eriko;
    • Mamesaya, Nobuaki;
    • Kobayashi, Haruki;
    • Omori, Shota;
    • Ko, Ryo;
    • Wakuda, Kazushige;
    • Ono, Akira;
    • Kenmotsu, Hirotsugu;
    • Murakami, Haruyasu;
    • Mori, Keita;
    • Harada, Hideyuki;
    • Endo, Masahiro;
    • Takahashi, Kazuhisa
    Publication type:
    Article
    38

    Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer.

    Published in:
    Thoracic Cancer, 2022, v. 13, n. 10, p. 1496, doi. 10.1111/1759-7714.14421
    By:
    • Nishioka, Naoya;
    • Naito, Tateaki;
    • Miyawaki, Taichi;
    • Yabe, Michitoshi;
    • Doshita, Kosei;
    • Kodama, Hiroaki;
    • Miyawaki, Eriko;
    • Iida, Yuko;
    • Mamesaya, Nobuaki;
    • Kobayashi, Haruki;
    • Omori, Shota;
    • Ko, Ryo;
    • Wakuda, Kazushige;
    • Ono, Akira;
    • Kenmotsu, Hirotsugu;
    • Murakami, Haruyasu;
    • Takayama, Koichi;
    • Takahashi, Toshiaki
    Publication type:
    Article
    39
    40
    41

    Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments.

    Published in:
    Investigational New Drugs, 2023, v. 41, n. 2, p. 356, doi. 10.1007/s10637-023-01353-8
    By:
    • Omori, Shota;
    • Muramatsu, Koji;
    • Kawata, Takuya;
    • Miyawaki, Eriko;
    • Miyawaki, Taichi;
    • Mamesaya, Nobuaki;
    • Kawamura, Takahisa;
    • Kobayashi, Haruki;
    • Nakashima, Kazuhisa;
    • Wakuda, Kazushige;
    • Ono, Akira;
    • Kenmotsu, Hirotsugu;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Sugino, Takashi;
    • Takahashi, Toshiaki
    Publication type:
    Article
    42
    43

    Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer.

    Published in:
    Investigational New Drugs, 2022, v. 40, n. 2, p. 403, doi. 10.1007/s10637-021-01191-6
    By:
    • Nishimura, Ari;
    • Ono, Akira;
    • Wakuda, Kazushige;
    • Kawabata, Takanori;
    • Yabe, Michitoshi;
    • Miyawaki, Taichi;
    • Miyawaki, Eriko;
    • Kodama, Hiroaki;
    • Nishioka, Naoya;
    • Mamesaya, Nobuaki;
    • Kobayashi, Haruki;
    • Omori, Shota;
    • Kenmotsu, Hirotsugu;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Harada, Hideyuki;
    • Takahashi, Toshiaki
    Publication type:
    Article
    44

    Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis.

    Published in:
    Investigational New Drugs, 2022, v. 40, n. 2, p. 411, doi. 10.1007/s10637-021-01183-6
    By:
    • Doshita, Kosei;
    • Kenmotsu, Hirotsugu;
    • Omori, Shota;
    • Tabuchi, Yuya;
    • Kawabata, Takanori;
    • Kodama, Hiroaki;
    • Nishioka, Naoya;
    • Miyawaki, Eriko;
    • Iida, Yuko;
    • Miyawaki, Taichi;
    • Mamesaya, Nobuaki;
    • Kobayashi, Haruki;
    • Ko, Ryo;
    • Wakuda, Kazushige;
    • Ono, Akira;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Mori, Keita;
    • Harada, Hideyuki;
    • Kaneko, Takeshi
    Publication type:
    Article
    45
    46

    Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 6, p. 1716, doi. 10.1007/s10637-021-01136-z
    By:
    • Takinami, Masaki;
    • Ono, Akira;
    • Kawabata, Takanori;
    • Mamesaya, Nobuaki;
    • Kobayashi, Haruki;
    • Omori, Shota;
    • Wakuda, Kazushige;
    • Kenmotsu, Hirotsugu;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Endo, Masahiro;
    • Kiyohara, Yoshio;
    • Yasui, Hirofumi;
    • Niwakawa, Masashi;
    • Takahashi, Toshiaki
    Publication type:
    Article
    47

    Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 6, p. 1732, doi. 10.1007/s10637-021-01140-3
    By:
    • Miyawaki, Taichi;
    • Kenmotsu, Hirotsugu;
    • Yabe, Michitoshi;
    • Kodama, Hiroaki;
    • Nishioka, Naoya;
    • Miyawaki, Eriko;
    • Mamesaya, Nobuaki;
    • Kobayashi, Haruki;
    • Omori, Shota;
    • Wakuda, Kazushige;
    • Ono, Akira;
    • Deguchi, Shoichi;
    • Mitsuya, Koichi;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Mori, Keita;
    • Harada, Hideyuki;
    • Hayashi, Nakamasa;
    • Takahashi, Kazuhisa;
    • Takahashi, Toshiaki
    Publication type:
    Article
    48

    Correction to: Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer.

    Published in:
    2021
    By:
    • Inoue, Hiroto;
    • Ono, Akira;
    • Kawabata, Takanori;
    • Mamesaya, Nobuaki;
    • Kawamura, Takahisa;
    • Kobayashi, Haruki;
    • Omori, Shota;
    • Wakuda, Kazushige;
    • Kenmotsu, Hirotsugu;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Yasui, Kazuaki;
    • Ogawa, Hirofumi;
    • Onoe, Tsuyoshi;
    • Endo, Masahiro;
    • Harada, Hideyuki;
    • Takahashi, Toshiaki
    Publication type:
    Correction Notice
    49

    Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 2, p. 571, doi. 10.1007/s10637-020-01005-1
    By:
    • Kodama, Hiroaki;
    • Wakuda, Kazushige;
    • Yabe, Michitoshi;
    • Nishioka, Naoya;
    • Miyawaki, Eriko;
    • Miyawaki, Taichi;
    • Mamesaya, Nobuaki;
    • Kawamura, Takahisa;
    • Kobayashi, Haruki;
    • Omori, Shota;
    • Ono, Akira;
    • Kenmotsu, Hirotsugu;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Endo, Masahiro;
    • Takahashi, Toshiaki
    Publication type:
    Article
    50

    Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 5, p. 1612, doi. 10.1007/s10637-020-00917-2
    By:
    • Inoue, Hiroto;
    • Ono, Akira;
    • Kawabata, Takanori;
    • Mamesaya, Nobuaki;
    • Kawamura, Takahisa;
    • Kobayashi, Haruki;
    • Omori, Shota;
    • Wakuda, Kazushige;
    • Kenmotsu, Hirotsugu;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Yasui, Kazuaki;
    • Ogawa, Hirofumi;
    • Onoe, Tsuyoshi;
    • Endo, Masahiro;
    • Harada, Hideyuki;
    • Takahashi, Toshiaki
    Publication type:
    Article